Piper Sandler Initiates Coverage On Apellis Pharmaceuticals with Neutral Rating, Announces Price Target of $46
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on Apellis Pharmaceuticals with a Neutral rating and a price target of $46.
May 31, 2024 | 9:55 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler has initiated coverage on Apellis Pharmaceuticals with a Neutral rating and a price target of $46.
The Neutral rating suggests that Piper Sandler does not expect significant short-term movement in Apellis Pharmaceuticals' stock price. The price target of $46 provides a benchmark for investors.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100